Asif Ali Sells 24,765 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 24,765 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of the sale, the chief financial officer directly owned 60,753 shares of the company’s stock, valued at $6,332,892.72. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Asif Ali also recently made the following trade(s):

• On Tuesday, January 27th, Asif Ali sold 46,203 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39.
• On Tuesday, January 20th, Asif Ali sold 8,588 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.48, for a total value of $708,338.24.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $98.97 on Monday. The company has a market cap of $6.32 billion, a P/E ratio of -48.28 and a beta of 2.23. The business has a fifty day simple moving average of $88.99 and a 200-day simple moving average of $82.68. Protagonist Therapeutics, Inc. has a 52 week low of $39.60 and a 52 week high of $105.69.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The business had revenue of $7.44 million for the quarter, compared to analysts’ expectations of $14.92 million. Sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: One‑year Phase 3 data for ICOTYDE (icotrokinra) presented at the 2026 AAD meeting showed durable skin clearance and a favorable safety profile for a once‑daily oral IL‑23 receptor targeted peptide — a meaningful clinical validation for the company’s lead psoriasis program that supports longer‑term upside. Read More.
• Positive Sentiment: At least one analyst raised their price target (reported +11.65% to $114.50), and multiple firms have recently bumped targets or issued “buy/overweight” views — analyst optimism following the data can underpin further gains if commercial potential is reinforced. Read More.
• Neutral Sentiment: Industry and strategy commentary highlights the company’s peptide platform and pipeline potential; useful context for long‑term investors but not an immediate catalyst. Read More.
• Negative Sentiment: Clustered insider selling on March 26 from multiple executives (CFO Asif Ali, Director Harold Selick, and insider Arturo Md Molina) — roughly 63,765 shares disclosed across filings for approximately $6.7M in proceeds — created visible near‑term selling pressure and is being read negatively by the market. SEC filings and trade details here: Read More. and Read More.
• Negative Sentiment: Recent quarterly results (Feb. 25) showed an EPS and revenue miss (EPS -$0.69 vs. -$0.53 est.; revenue $7.4M vs. $14.9M est.), a reminder of continuing execution and commercialization risks for a clinical‑stage biotech. Read More.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PTGX. Farallon Capital Management LLC grew its stake in Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after buying an additional 24,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after acquiring an additional 1,156,461 shares during the period. BVF Inc. IL raised its stake in shares of Protagonist Therapeutics by 24.7% in the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after acquiring an additional 636,026 shares during the period. State Street Corp lifted its holdings in shares of Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after acquiring an additional 500,924 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after acquiring an additional 1,262,977 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PTGX. Jefferies Financial Group reissued a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. JPMorgan Chase & Co. increased their price target on shares of Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Leerink Partners lifted their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Finally, Barclays boosted their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $107.31.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.